GlaxoSmithKline plc (LON:GSK) announced a dividend on Wednesday, May 1st, Upcoming.Co.Uk reports. Stockholders of record on Thursday, May 16th will be given a dividend of GBX 19 ($0.25) per share on Thursday, July 11th. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, May 16th. The official announcement can be accessed at this link.
GSK opened at GBX 1,502 ($19.63) on Friday. GlaxoSmithKline has a one year low of GBX 1,408.80 ($18.41) and a one year high of GBX 1,648.80 ($21.54). The company has a current ratio of 0.72, a quick ratio of 0.45 and a debt-to-equity ratio of 942.07. The company has a market cap of $74.30 billion and a PE ratio of 19.13.
In other news, insider Manvinder Singh Banga bought 458 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were bought at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Also, insider Emma Walmsley sold 66,159 shares of the stock in a transaction on Friday, February 15th. The stock was sold at an average price of GBX 1,585 ($20.71), for a total transaction of £1,048,620.15 ($1,370,207.96). Over the last quarter, insiders acquired 3,486 shares of company stock worth $5,402,516.
Several equities analysts recently weighed in on the stock. UBS Group restated a “neutral” rating and issued a GBX 1,630 ($21.30) price objective on shares of GlaxoSmithKline in a report on Thursday, May 2nd. Deutsche Bank restated a “hold” rating and issued a GBX 1,550 ($20.25) price objective on shares of GlaxoSmithKline in a report on Friday, May 3rd. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline in a report on Thursday, May 2nd. Credit Suisse Group set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, May 2nd. Finally, Liberum Capital restated a “hold” rating on shares of GlaxoSmithKline in a report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of GBX 1,526.14 ($19.94).
ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline plc Announces Dividend of GBX 19 (GSK)” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2019/05/11/glaxosmithkline-plc-announces-dividend-of-gbx-19-gsk.html.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.